Summary
The SARS-CoV-2 pandemic has unprecedented implications for public health, social life, and the world economy. Because approved drugs and vaccines are limited or not available, new options for COVID-19 treatment and prevention are in high demand. To identify SARS-CoV-2-neutralizing antibodies, we analyzed the antibody response of 12 COVID-19 patients from 8 to 69 days after diagnosis. By screening 4,313 SARS-CoV-2-reactive B cells, we isolated 255 antibodies from different time points as early as 8 days after diagnosis. Of these, 27 potently neutralized authentic SARS-CoV-2 with IC100 as low as 0.04 μg/mL, showing a broad spectrum of variable (V) genes and low levels of somatic mutations. Interestingly, potential precursor sequences were identified in naive B cell repertoires from 48 healthy individuals who were sampled before the COVID-19 pandemic. Our results demonstrate that SARS-CoV-2-neutralizing antibodies are readily generated from a diverse pool of precursors, fostering hope for rapid induction of a protective immune response upon vaccination.
【저자키워드】 COVID-19, neutralizing antibody, SARS-CoV-2, monoclonal antibody, 2019-nCoV, single B cell analysis, 【초록키워드】 Treatment, public health, Vaccine, vaccination, antibody, SARS-CoV-2 pandemic, COVID-19 pandemic, B cells, Diagnosis, B cell, SARS-CoV-2-neutralizing antibodies, COVID-19 patient, somatic mutations, approved drug, protective immune response, sequence, precursors, precursor, implication, neutralized, analyzed, identify, different time point, the antibody response, healthy individual, SARS-CoV-2-neutralizing antibody, 【제목키워드】 longitudinal, potent,